If HRT helps hot flushes but not dryness, what next?
If HRT helps hot flushes but not dryness, what next? Add local therapy targeted to genitourinary syndrome of menopause (GSM)—usually vaginal oestrogen or vaginal DHEA—alongside a scheduled vaginal moisturiser and a suitable lubricant. Fine-tune placement (especially at the entrance), review irritants, and consider pelvic floor physiotherapy or psychosexual support for dyspareunia. Escalate step-wise and aim for the lowest effective maintenance. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
If HRT helps hot flushes but not dryness, what next? Systemic hormone replacement therapy (HRT) can calm vasomotor symptoms, sleep and mood, yet many still have vaginal dryness, stinging with urine on delicate skin, micro-tears, dyspareunia and urinary urgency/frequency. That’s because genitourinary syndrome of menopause (GSM)—also known as vaginal atrophy—reflects very low oestrogen within the local tissues. The next step is to add a local option: vaginal oestrogen (cream, pessary/tablet or ring) or vaginal DHEA. These act directly on the vulvo-vaginal epithelium and the urethral/bladder entrance to restore moisture, elasticity, a healthier pH and comfort over weeks. Pair this with a scheduled vaginal moisturiser (many prefer hyaluronic-acid gels) several times weekly and a compatible personal lubricant for higher-friction moments.
Get the basics right first. Review irritants (fragranced washes, bubble baths, tight kit, frequent liners), rinse with lukewarm water and use a bland emollient as a soap substitute externally. Build unhurried, pleasure-led intimacy; add lubricant early and generously. If the tender spot is the entrance (vestibule), ensure treatment actually reaches it: creams allow fingertip placement to the posterior fourchette; with tablets/pessaries or a ring, many also use a thin smear of non-hormonal moisturiser externally on alternate nights.
What to expect when adding local therapy. Early relief (less “sandpaper” friction, fewer micro-tears) often appears in 2–4 weeks, with fuller improvements in moisture, elasticity and pH by 8–12 weeks. Most regimens use a short loading phase then step down to the lowest effective maintenance (often twice weekly). If pain has led to pelvic floor guarding, add pelvic health physiotherapy; psychosexual therapy can rebuild confidence and reduce fear-avoidance patterns.
When to think beyond GSM. New malodorous or grey/green discharge, intense itching with thick white discharge, ulcers or rapidly changing white plaques, post-menopausal bleeding, fever, severe pain or visible blood in urine point away from straightforward GSM and warrant assessment. Likewise, persistent entrance-burning despite tissue rehydration may suggest vestibulodynia or pelvic floor over-activity, which benefit from targeted therapy.
Planning your pathway and expectations. Most people do best with a clear, stepped plan: foundations → add local therapy → review technique/placement at 6–12 weeks → maintain the minimum effective dose/frequency. For a plain-English overview of how treatment steps are sequenced and answers to common questions in clinic see our FAQs. If you are weighing costs or timing, we can outline typical review points and maintenance once comfortable.
Where newer options fit. Energy-based devices (vaginal laser/radiofrequency) and regenerative injectables (e.g., platelet-rich plasma or polynucleotides) are not first-line for GSM; evidence is evolving and they should be considered only after guideline-led care, with a discussion of benefits, risks and cost. Your plan remains personalised and can be adapted over time.
Clinical Context
Who tends to need local therapy despite HRT? People with persistent vaginal dryness/GSM, dyspareunia, superficial fissures, or urinary urgency/frequency. Those after surgical menopause or on lower HRT doses for tolerability often improve only when a local option is added. If penetration remains sharp or burning at the entrance, consider pelvic floor over-activity or vestibulodynia; pelvic health physiotherapy and paced, comfort-first intimacy help.
Who should seek review before escalating? Anyone with post-menopausal bleeding, ulcers or rapidly changing vulval skin (possible dermatoses such as lichen sclerosus), fever or severe pain, malodorous discharge, or visible blood in urine. People with a history of hormone-sensitive cancer should make decisions about local oestrogen or vaginal DHEA together with oncology and menopause teams. Alternatives for those avoiding hormones include scheduled moisturisers (often with hyaluronic acid), tailored lubricants and behavioural strategies; review response at 6–12 weeks and adjust to the lowest effective maintenance once comfortable.
Evidence-Based Approaches
UK guidance supports a stepped approach. The NICE Menopause Guideline (NG23) recommends offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life, with or without systemic HRT. Patient-facing advice on symptoms and self-care appears on the NHS page for vaginal dryness.
Cochrane reviews report that local oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo across creams, tablets/pessaries and rings, with low systemic absorption at licensed doses; see the Cochrane Library. Prescribing-level product information and cautions for UK preparations (oestrogen and prasterone/DHEA) are set out in the British National Formulary (BNF). For mechanisms and terminology (GSM/atrophy; pH; lactobacilli) and broader management overviews, see a representative peer-reviewed summary indexed on PubMed.
Applying the evidence: If HRT calms flushes but dryness persists, add local therapy, optimise placement (especially the vestibule), continue moisturiser/lubricant support, and review at 6–12 weeks. Maintain the minimum effective regimen thereafter, and reassess for mimics or pelvic floor drivers if progress stalls.